Teppo Konsta, Jaakkola Jussi, Biancari Fausto, Halminen Olli, Linna Miika, Haukka Jari, Putaala Jukka, Mustonen Pirjo, Kinnunen Janne, Luojus Alex, Itäinen-Strömberg Saga, Hartikainen Juha, Aro Aapo L, Juhani Airaksinen K E, Lehto Mika
University of Turku, Turku, Finland.
Heart Unit, Satakunta Central Hospital, Pori, Finland.
Int J Cardiol Heart Vasc. 2022 Jun 13;41:101070. doi: 10.1016/j.ijcha.2022.101070. eCollection 2022 Aug.
In patients with atrial fibrillation (AF), socioeconomic disparities have been reported in the use of oral anticoagulant therapy and outcomes, but whether income also affects the utilization of antiarrhythmic therapies (AATs) for rhythm control is unknown. We assessed the hypothesis that AF patients with higher income are more likely to receive AATs.
The nationwide retrospective registry based FinACAF cohort study covers all patients with AF from all levels of care in Finland. Patients were divided in AF diagnosis year and age-group specific income quintiles according to their highest annual income during 2004-2018. The primary outcome was the use of any AAT, including cardioversion, catheter ablation, and fulfilled antiarrhythmic drug (AAD) prescription.
We identified 188 175 patients (mean age 72.6 ± 13.0 years; 49.6% female) with incident AF during 2010-2018. Patients in higher income quintiles had consistently higher use of all AAT modalities. When compared to patients in the lowest income quintile, the adjusted incidence rate ratios (95% CI) in the highest quintile were 1.53 (1.48-1.59) for any AAT, 1.71 (1.61-1.81) for AADs, 1.43 (1.37-1.49) for cardioversion, and 2.00 (1.76-2.27) for catheter ablation. No temporal change during study period was observed in the magnitude of income disparities in AAT use, except for a decrease in income-related differences in the use of AADs.
Profound income-related disparities exist in AAT use among patients with AF in Finland, especially in the use catheter ablation.
在心房颤动(AF)患者中,口服抗凝治疗的使用及治疗效果存在社会经济差异,但收入是否也会影响用于节律控制的抗心律失常治疗(AAT)的使用尚不清楚。我们评估了高收入AF患者更有可能接受AAT这一假设。
基于全国性回顾性登记的FinACAF队列研究涵盖了芬兰各级医疗机构的所有AF患者。根据患者在2004年至2018年期间的最高年收入,将其分为AF诊断年份和年龄组特定的收入五分位数。主要结局是使用任何AAT,包括心脏复律、导管消融和已开具的抗心律失常药物(AAD)处方。
我们识别出2010年至2018年期间188175例新发AF患者(平均年龄72.6±13.0岁;49.6%为女性)。收入五分位数较高的患者对所有AAT方式的使用一直较高。与收入最低五分位数的患者相比,最高五分位数患者的任何AAT调整发病率比(95%CI)为1.53(1.48 - 1.59),AAD为1.71(1.61 - 1.81),心脏复律为1.43(1.37 - 1.49),导管消融为2.00(1.76 - 2.27)。除AAD使用的收入相关差异有所减少外,研究期间未观察到AAT使用中收入差距大小的时间变化。
芬兰AF患者在AAT使用方面存在与收入相关的显著差异,尤其是在导管消融的使用上。